Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Current Protocols in Pharmacology|February 2, 2012
5-Hydroxytryptamine receptor assaysKatherine W Figueroa, Graeme R Martin, M Teresa Pulido-RiosCurrent Protocols in Pharmacology|February 2, 2012
In vitro muscarinic receptor radioligand-binding assaysTod Steinfeld, M Teresa Pulido-Rios, Scott Armstrong, et al.Current Protocols in Pharmacology|February 2, 2012
In vivo pharmacodynamic assays for M2 and M3 muscarinic receptorsScott Armstrong, Tod Steinfeld, M Teresa Pulido-Rios, et al.Current Protocols in Pharmacology|February 2, 2012
In vitro isolated tissue functional muscarinic receptor assaysM Teresa Pulido-Rios, Tod Steinfeld, Scott Armstrong, et al.Journal of Inflammation (London, England)|December 12, 2017
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapyDavid T Beattie, M Teresa Pulido-Rios, Fei Shen, et al.The Journal of Pharmacology and Experimental Therapeutics|August 8, 2014
Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist propertiesSharath S Hegde, Adam D Hughes, Yan Chen, et al.Journal of Medicinal Chemistry|January 29, 2015
Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β₂ agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)Adam D Hughes, Yan Chen, Sharath S Hegde, et al.Pharmacology Research & Perspectives|May 9, 2018
Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissuesSharath S Hegde, M Teresa Pulido-Rios, Mark A Luttmann, et al.Journal of Crohn'S & Colitis|March 13, 2020
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine ProgrammeWilliam J Sandborn, Deanna D Nguyen, David T Beattie, et al.Pageof 1